Metabolic syndrome in youth with bipolar spectrum disorders treated with second-generation antipsychotics: baseline results from the community-based pragmatic MOBILITY Trial.

ABSTRACT: Metabolic syndrome (MetS) in obese youth in the general population is about 29%. The aim of this study is to identify the baseline prevalence and clinical characteristics of MetS in a sample of overweight/obese youth with bipolar spectrum disorders treated with second-generation antipsychotics (SGAs). The MOBILITY trial enrolled overweight/obese youth 8-19 years of age with a lifetime diagnosis of a bipolar spectrum disorder who were continuing or starting treatment with an SGA (November/2015-December/2022). Baseline height, weight, body mass index (BMI), blood pressure, fasting lipid profile, glucose, hemoglobin A1c, and insulin were collected. Logistic regression was used to estimate the odds of MetS and each of its component criteria and correlations with demographic factors. Of 1565 ra

SUBMITTER: Higdon C 

PROVIDER: S-EPMC12507931 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature